Amaya Zaratiegui
Novo Nordisk (Denmark)1 paperORCID 0009-0007-6522-2703OpenAlex
Papers
Nature MedicineHuman trial
Semaglutide curbs kidney vascular resistance and fibrosis
In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to…In 106 people with diabetes and kidney disease, 52 weeks of semaglutide reduced vascular resistance and stabilized markers of fibrosis compared to placebo.